Deutsch | English | по-русски | Türkçe 

Publikationen 2017

47.

Kassubek R, Bullinger L, Kassubek J, Dreyhaupt J, Ludolph AC, Althaus K, Lewerenz J.

Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.

J Neurol. 2017 Feb 28. [Epub ahead of print]

46.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Lancet Oncol. 2017 Feb 21. [Epub ahead of print]

45.

Liu X, Pichulik T, Wolz O, Dang TM, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, Münzenmayer L, Wahl S, Rieber N, Kümmerle-Deschner J, Yazdi A, Franz-Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stilgenbauer S, Grimbacher B, Miller L, Brunner C, Wolz C, Weber AN.

Human NLRP3 inflammasome activity is regulated by and potentially targetable via BTK.

J Allergy Clin Immunol. 2017 Feb 16. [Epub ahead of print]

44.

Rohde M, Bonn BR, Zimmermann M, Lange J, Möricke A, Klapper W, Oschlies I, Szczepanowski M, Nagel I, Schrappe M, Loeffler M, Siebert R, Reiter A, Burkhardt B; ICGC-MMML-Seq; MMML-MYC-SYS.

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols.

Haematologica. 2017 Feb 16. [Epub ahead of print]

43.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; and for the German-Austrian AMLSG.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Leukemia. 2017 Feb 3. [Epub ahead of print]

42.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 2017 Jan 27. [Epub ahead of print]

41.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Leukemia. 2017 Jan 19. [Epub ahead of print].

40.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT.

Leukemia. 2017 Jan 16. [Epub ahead of print].

39.

Chakrabortty S, Agrawalla BK, Stumper A, Vegi NM, Fischer S, Reichardt C, Kögler M, Dietzek B, Feuring-Buske M, Buske C, Rau S, Weil T.

Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications.

J Am Chem Soc. 2017 Jan 18. [Epub ahead of print].

38.

Roberts AW, Stilgenbauer S, Seymour JF, Huang DC.

Venetoclax in patients with previously treated chronic lymphocytic leukemia.

Clin Cancer Res. 2017 Jan 18. [Epub ahead of print].

37.

Gerstung M,* Papaemmanuil E,* Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H,* Campbell PJ.*

Precision oncology for acute myeloid leukemia using a knowledge bank approach.

Nat Genet. 2017 Jan 16. [Epub ahead of print]. *Equal contribution

36.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG).

Leukemia. 2017 Jan 16. [Epub ahead of print].

35.

Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Haematologica. 2017 Jan 12. [Epub ahead of print] No abstract available.

34.

Fürst D, Niederwieser D, Bunjes D, Wagner EM, Gramatzki M, Wulf G, Müller CR, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J.

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

Haematologica. 2017 Jan 5. [Epub ahead of print].

33.

Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.

Ann Hematol. 2017 Jan 5. [Epub ahead of print].

32.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2016 Dec 12. [Epub ahead of print].

31.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia..

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Lancet Oncol. 2016 Dec 9. [Epub ahead of print].

30.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Haematologica. 2016 Dec 15. [Epub ahead of print]. No abstract available.

29.

Weißflog G, Hönig K, Gündel H, Lang D, Niederwieser D, Döhner H, Vogelhuber M, Mehnert A, Ernst J.

Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners.

Support Care Cancer. 2016 Dec 16. [Epub ahead of print].

28.

Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B.

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial.

Lancet Infect Dis. 2016 Dec 19. [Epub ahead of print].

27.

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C.

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Leukemia. 2016 Dec 26. [Epub ahead of print].

26.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

Leukemia. 2016 Dec 2. [Epub ahead of print].

25.

Qu Y, Siggens L, Cordeddu L, Gaidzik VI, Karlsson K, Bullinger L, Döhner K, Ekwall K, Lehmann S, Lennartsson A

Cancer specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.

Blood. 2016 Dec 21. [Epub ahead of print].

24.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichman M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Leukemia. 2016 Nov 24. [Epub ahead of print].

23.

Hillenbrand A, Gruener B, Kratzer W, Kern P, Graeter T, Barth TF, Buttenschoen K, Henne-Bruns D.

Impact of Safe Distance on Long-Term Outcome After Surgical Therapy of Alveolar Echinococcosis.

World J Surg. 2016 Nov 7. [Epub ahead of print].

22.

Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O.

Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.

Exp Hematol. 2016 Nov 5. [Epub ahead of print].

21.

Pankrath AL, Weißflog G, Mehnert A, Niederwieser D, Döhner H, Hönig K, Gündel H, Vogelhuber M, Friedrich M, Ernst J.

The relation between dyadic coping and relationship satisfaction in couples dealing with haematological cancer.

Eur J Cancer Care (Engl). 2016 Oct 24. [Epub ahead of print].

20.

Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M.

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.

Leukemia. 2016 Oct 24. [Epub ahead of print].

19.

Schlenk RF*, Stegelmann F*, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K, *equal contribution.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Leukemia. 2016 Oct 24. [Epub ahead of print].

18.

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S.

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol. 2016 Aug 29. [Epub ahead of print].

17.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

J Clin Oncol. 2016 Jul 11. [Epub ahead of print].

16.

Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S.

Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.

Br J Haematol. 2016 Jul 8. [Epub ahead of print]. No abstract available.

15.

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre trial.

Eur J Haematol. 2017 Mar;98(3):254-262. Epub 2016 Dec 1.

14.

Schönsteiner S*, Bauder Mißbach H, Benner A, Mack S, Hamel T, Orth M, Landwehrmeyer B, Süßmuth S, Geitner C, Mayer‑Steinacker R, Riester A, Prokein A, Erhardt E, Kunecki J, Eisenschink A, Rawer R, Döhner H, Kirchner R, Schlenk RF

A randomized exploratory phase 2 study in patients with chemotherapy‑related peripheral neuropathy evaluating whole‑body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.

Exp Hematol Oncol. 2017 Feb 7;6:5. eCollection 2017.

13.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Int J Mol Sci. 2017 Feb 15;18(2).

12.

Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S.

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.

Onco Targets Ther. 2017 Feb 7;10:645-656. eCollection 2017.

 

11.

Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA.

The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease.

Adv Parasitol. 2017;96:259-369.Epub 2017 Feb 8.

10.

Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A.

Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.

Bone Marrow Transplant. 2017 Feb;52(2):238-244. Epub 2016 Sep 19.

9.

Dezsényi B, Strausz T, Makrai Z, Csomor J, Danka J, Kern P, Rezza G, Barth TF, Casulli A.

Autochthonous human alveolar echinococcosis in a Hungarian patient.

Infection. 2017 Feb;45(1):107-110. Epub 2016 Jun 28.

8.

Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C.

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.

Oncotarget. 2017 Jan 31;8(5):7678-7690.

7.

Kurth F, Develoux M, Mechain M, Malvy D, Clerinx J, Antinori S, Gjørup IE, Gascon J, Mørch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-Nübling G, Neumayr A, Hachfeld A, Schmid ML, Antonini P, Lingscheid T, Kern P, Kapaun A, da Cunha JS, Pongratz P, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T.

Severe malaria in Europe: an 8-year multi-centre observational study.

Malar J. 2017 Jan 31;16(1):57.

6.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017 Jan 26;129(4):424-447. Epub 2016 Nov 28.

5.

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.

Blood. 2017 Jan 19;129(3):319-323.

4.

Neuchel C, Fürst D, Niederwieser D, Bunjes D, Tsamadou C, Wulf G, Pfreundschuh M, Wagner E, Stuhler G, Einsele H, Schrezenmeier H, Mytilineos J.

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.

PLoS One. 2017 Jan 20;12(1):e0169512.

3.

Buske C.

Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?

Lancet Haematol. 2017 Jan;4(1):e4-e5.

2.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group.

Haematologica. 2017 Jan;102(1):85-93.

 

1.

Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T.

Response Evaluation in Head and Neck Oncology: Definition and Prediction.

ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23. Epub 2017 Feb 24.

gepunktete blaue Linie 1000px breit